| 产品描述: | BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) research |
| 靶点: |
GSK3α:66 nM (IC50);GSK3α:4.8 μM (Kd);GSK-3β(WT):515 nM (IC50);GSK-3 |
| 体内研究: |
BRD0705 (30 mg/kg; oral gavage; twice daily; NSG mice) treatment impairs leukemia initiation and prolongs survival in AML mouse models |
| 参考文献: |
1. Wagner FF, et al. Exploiting an Asp-Glu switch in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.111 ml |
15.556 ml |
31.112 ml |
| 5 mM |
0.622 ml |
3.111 ml |
6.222 ml |
| 10 mM |
0.311 ml |
1.556 ml |
3.111 ml |
| 50 mM |
0.062 ml |
0.311 ml |
0.622 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |